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Introduction
Obsessive-compulsive disorder (OCD) is a common psychiatric disorder, creating
harmful effects on social and occupational functioning for OCD patients.. OCD is characterized
by “persistent thoughts (obsessions) and repetitive ritualistic behaviors (compulsions).”1
Common obsessions include contamination fears and forbidden sexual thoughts, while common
compulsions include cleaning and counting rituals.2 Many patients experience OCD symptoms
beginning in childhood, leading to a chronic and debilitating disease when left untreated.2
Currently, OCD has an estimated lifetime prevalence of 2%, affecting both genders equally.1 In
1990 (the most recent year for which data is available), it was estimated that the total costs of
OCD were 8.4 billion dollars;3 this has likely gone up tremendously in the past two decades. In
addition, from the years 1995-1996, 2,043 individuals from a 1,728,480 person health
maintenance organization (HMO) had the clinical diagnosis of OCD.4
Currently, the exact cause of OCD is unknown, however at this time it has been thought
that the cause is due to a combination of genetic and environmental factors.5 With many studies
underway, “recent evidence highlights an abrupt onset of OCD symptoms in some cases in the
context of group A beta-hemolytic streptococcal (GABHS) infection.”5 With specific disease
causes largely unknown, treatment is often generalized in nature.5 Common conventional
treatments are pharmacotherapy with high-dose serotonergic antidepressant medications or
behavioral psychotherapy, or a combination of the two5. Despite treatment advances, it is
estimated that current treatments provide a “mean of 40% to 60% symptom reduction in half of
the patients,” leaving many with ongoing symptoms.1 In addition, 10% of patients will be
plagued with severe, treatment-refractory OCD.1 For a portion of treatment-refractory patients,
neurosurgical treatment may serve as a more effective, long-lasting resort.
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Deep brain stimulation (DBS) is a neurosurgical treatment in which electrodes are
implanted in specific areas of the brain, selected according to the type of symptoms being
targeted.1 The electrodes send out electrical impulses to the neuronal tissue of the target brain
location.1 Although not widely used, DBS is promising in that it may provide an alternate
treatment option for refractory OCD, with successful outcomes having already been shown.
Objective
The objective of this systematic review is to determine whether or not deep brain stimulation
(DBS) is an effective treatment for refractory obsessive compulsive disorder (OCD) in adults.
Methods
All three studies included in this review met the following criteria. The population
included adults at least 18 years of age with treatment refractory OCD and a minimum score of
25 on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS).1,6,7 The Abelson et al6 and
Denys et al1 studies were both double-blind, sham-controlled randomized controlled trials, while
the third study used, Goodman et al7, was a blinded, staggered-onset randomized controlled trial.
The intervention used was deep brain stimulation of the following areas of the brain: ventral
anterior limb of the internal capsule and adjacent ventral striatum (Goodman et al7), nucleus
accumbens of the ventral striatum (Denys et al1), and the anterior limb of each internal capsule
(Abelson et al6). All studies reviewed compared the treatment group to a control group which
received random “sham stimulation.”1,6,7 The main outcome measured in each of the studies was
the severity of OCD symptoms based on changes from baseline in OCD symptoms using YBOCS.1,6,7 This outcome qualifies as patient oriented evidence that matters (POEM).
The author searched for articles using PubMed, Medline and Cochrane Databases using
the keywords “obsessive-compulsive disorder,” “refractory,” and “deep brain stimulation.” All
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articles selected were published in English, in peer-reviewed journals. The inclusion criteria
were studies that were randomized controlled trials published after 1996 and that had patientoriented outcomes (POEMS). The exclusion criteria were articles that included patients under
the age of 18 years old, patients that were diagnosed with substance abuse, or lastly, patients that
were diagnosed with psychoses. The statistics included were p-values and Numbers Needed to
Treat (NNT).
Table 1: Demographics and Characteristics of Included Studies
Study

Type

#
Pts

Age

Inclusion Criteria

Exclusion Criteria

W/D

Interventions

Denys et
al1

Doubleblind,
shamcontrolled
RTC

16

2159

Pts. who had
clinically significant
DSM-IV comorbid
diagnoses, who had
severe personality
disorders, who had
clinically significant
and unstable
neurologic or
medical illnesses

2

Treatment with
bilateral DBS of the
nucleus accumbens

Abelson
et al6

Doubleblind,
shamcontrolled
RCT

4

2752

Pts. who had no
history of psychosis
and who has no
current substance
abuse

N/A

Quadripolar
stimulating
electrodes placed
stereotaxically in the
anterior limb of each
internal capsule;
connected via
subcutaneous wires
to implantable pulse
generators placed in
the subclavicular
area

Goodman
et al7

Blinded,
staggeredonset RCT

6

2752

Pts. diagnosed with primary
OCD using DSM-IV, ≥28 on
Y-BOCS, >5 year history of
OCD, exp substantial
functional impairment
according to DSM-IV
Criterion C, GAF score of 45
or less, experienced
refractoriness to therapy,
partook in at least 1 CBR for
≥16 sessions
Patients who had a Y-BOCS
scale ≥25, a GAF score less
than 44, who had multiple
unsuccessful treatment
attempts with anti-obsessional
mediation, who partook in
medication trials on at least
four anti-obsessional
medications proven effective,
who had exposure to various
medication combinations, who
received 12 weeks of CBT
w/o meaningful benefit and
who were in “good” general
health
Patients who met DSM-IV
score for OCD, ≥28 on YBOCS, 5-year history of
treatment refractory OCD
symptoms since age 18,
partook in an adequate trial of
clomipramine, and at least two
SSRIs (fluoxetine,
fluvoxamine, citalopram,
sertraline, paroxetine), with
addition of one or more of the
aforementioned drugs with at
least two of the following:
clonazepam, haloperidol,

Patients who had a
lifetime diagnosis of
psychosis or bipolar
disorder, who had
chemical abuse
issues within the
previous six months,
who had a primary
diagnosis of
depression within the
previous year, who
had a current DSMIV Axis II diagnosis
from cluster A, and

N/A

Treatment with DBS
electrode arrays
placed bilaterally in
an area spanning the
ventral anterior limb
of the internal
capsule and adjacent
ventral striatum.
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risperidone, olanzapine or
gabapentin and who partook
in an adequate trial of CBT

who had the presence
of brain pathology

Outcomes Measured
Each article’s primary outcome measured was OCD symptom severity based on the YaleBrown Obsessive Compulsive Scale (Y-BOCS). The Y-BOCS is a clinician rated scale with 10
different items scored from either 0 (no symptoms) to 40 (severe symptoms).8 This scale has
questions dealing with both obsessions and compulsions. The scores then represent a stage of
OCD, with a score of 0-7 indicating subclinical OCD, 8-15 as mild OCD, 16-23 as moderate
OCD, 24-31 as severe OCD and 32-40 as extreme OCD.8 Goodman et al7 specified that each YBOCS assessment was conducted by either the principle investigator, a clinical psychiatrist, or a
psychiatric research nurse, Denys et al1 specified that assessments were conducted by a trained
investigator; however, Abelson et al6 failed to specify who conducted the assessments.
Each study also assessed secondary outcome measures such as the Hamilton Depression
Scale (HAM-D) and the Hamilton Anxiety Scale (HAM-A). This review is limited to results
based on the severity of OCD symptoms using the Y-BOCS assessment.
Results
In Goodman et al7, a responder was defined as a subject with both a 35% reduction in
score from baseline and an actual Y-BOCS score of 16 or less at the time of assessment. This
definition of a responder created a set of dichotomous data; responders and non-responders. YBOCS scores were also analyzed as continuous data with repeated-measure analysis of variance
(ANOVA).7 All six of the study’s participants were implanted with neuro-stimulation. At one
month post-implantation, three of the subjects received active DBS while the remainder of the
subjects received sham stimulation.7 At two months, those receiving sham stimulation were
converted to active DBS.7 At this two month mark, all study participants were receiving active
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DBS7. All of the above actions were conducted in a double blind setting. Graph 17 demonstrates
Y-BOCS score progression over time, with 1A demonstrating the scores of the early DBS
activation group and 1B demonstrating the scores of the late DBS activation group. It is
important to note that unbeknownst to subject 1 or the treatment team, subject 1’s right-sided
battery was depleted between 11 and 12 months.7 The ineffective DBS battery led to an OCD
exacerbation (black triangle) and then a subsequent normalization (gray triangle) shortly after
battery replacement7.
Graph 1. Y-BOCS Score vs. Time Since DBS Surgery

a. This graph comes directly from Goodman et al7

Visual inspection of Graph 17 demonstrates very little reduction in Y-BOCS scores with
the control subjects (sham stimulation) and an obvious varying decrease in Y-BOCS scores upon
DBS activation. Overall, there was a significant decrease in Y-BOCS scores over time, with a
decrease of 15.67 ± 11.60 after 12 months of DBS activation (p-value of 0.0392 using
ANOVA).7 Four of the six participants were classified as responders. The RBI and ABI were
calculated to be 67% with NNT being 2 patients, as demonstrated in Table 27.
Table 2. Key Values from the Three RCT’s Being Reviewed
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Goodman et
al7
Abelson et
al6
Denys et al1

p-value
0.0392

CER
0%

EER
67%

RBI
67%

ABI
67%

NNT
2 patients

N/A

0%

25%

25%

25%

4 patients

0.004

0%

56%

56%

56%

2 patients

Overall, the Goodman et al7 study was relatively safe, with all original participants
completing the trial in its totality. Compliance was not specifically noted, however it is assumed
that actual DBS compliance was 100% being that stimulators were neuro-surgically implanted,
with no indication that the DBS stimulation was removed throughout the trial. It is important to
note that unexpected adverse events did not occur in response to implantation, such as seizures or
cerebral hemorrhage.7 Table 3 demonstrates the adverse events of stimulation observed
throughout the trial. Only one serious event was noted upon which hospitalization was required7.
Table 3. Goodman et al7 Adverse Events
Adverse Event
Contralateral smile w/ mirth
Hypomania
Serious AE (unspecified, but
required hospitalization)
Bipolar Disorder

N
5
4
1

% Affected
83.333%
66.667%
16.667%

0

0.000%

In Abelson et al6, a responder was defined as one who experienced ≥ 35% decline in YBOCS score from baseline. According to Abelson et al6, “the literature indicates that the anterior
capsulotomy produces a 35% improvement in OCD symptoms in about 45% of patients who
receive the operation,”6 hence the justification of this study’s responder definition. It is
important to note that an exploratory phase of the study was performed prior to the double-blind
phase. During this phase, which was performed at a General Clinical Research Center, a range
of stimulation parameters were tested to determine tolerability and effects of stimulation.6 This
exploratory phase helped determine evidence of stimulation benefit and/or “maximum levels of
undetectable sitmulation.”6
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In the double-blind phase of this study (the only phase being analyzed in this review), one
out of four subjects were classified as responders. Throughout the double-blind study, there were
a total of eight ON periods (active stimulation) and eight OFF periods (sham stimulation).6 As
seen in Table 3, Subject 3 (responder) demonstrated a 67% reduction in Y-BOCS score from
baseline during the ON periods, while only demonstrating a 23% reduction in Y-BOCS score
from baseline during the OFF periods.6 Subject 2 (non-responder) demonstrated a 13% change
from baseline during ON stimulation and a 19% change from baseline during OFF stimulation,
demonstrating some sort of placebo effect.6 The mean reduction from baseline in Y-BOCS with
stimulators ON was 19.8% (SD 29.8), while the mean with stimulators OFF was 10.5% (SD
17.8).6 As Table 2 demonstrates, the NNT was 4 patients (the entire subject population for this
study).
Table 3. Abelson et al6 Subject Characteristics and Mean Y-BOCS Scores during Double Blind
Testing
Subject 1

Subject 2

Subject 3

Subject 4

52

27

48

34

OCD Duration (years) 46

11

16

17

Gender

Male

Female

Female

Male

Symptoms

Repeating, reentering, Intrusive images (of
order/symmetry,
sex, violence), mental
counting
arranging, counting,
cleaning

Contamination, cleaning,
checking/repeating,
symmetry

Repeating,
“just right”
behavior

Baseline Y-BOCS
Score

39

36

30

26

Mean (% decline in
Y-BOCS from
baseline)—ON

37.5 (4)

31.5 (13)

10 (67)

27 (-4)

Mean (% decline in
Y-BOCS from
baseline)a—OFF

39 (0)

29 (19)

23 (23)

26 (0)

Side Effects of
Stimulation

None

Throbbing, buzzing,
nausea, diarrhea

Tingling

Jaw sensations

Age

a. All information from this table was taken directly from Abelson et al6
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Also seen in Table 3 are the DBS side effects that each of the four subjects experienced
in the Abelson et al6 study. Somatic symptoms such as throbbing, buzzing, nausea, diarrhea,
tingling and jaw sensations were noted.6 Overall, no evidence of cognitive impairment or
personality changes were noted from either patients or family members.6 Despite side effects,
there was a 100% retention rate of study subjects throughout the double-blind phase of the trial.6
Similar to Abelson et al6, in the study performed by Denys et al1, responders were
defined as those with a ≥ 35% decrease in Y-BOCS score from baseline. Prior to the doubleblind, sham controlled phase of the Denys et al1 study, there was an open stimulation phase.
This open DBS phase lasted 8 months, with subjects being evaluated every 2 weeks for OCD
symptom severity and optimal stimulation parameters.1 At the conclusion of the 8 months, the
double-blind, sham-controlled phase began. Subjects were randomly assigned two periods of 2
weeks each, with active stimulation in one period and sham stimulation during the other period.1
Subjects were assessed at baseline, after their first 2 week period of either active or sham
stimulation, and then after the second 2 week period.1 It should be noted that two subjects
refused to enter the double-blind, sham controlled crossover phase of experimentation. One
subject feared losing the positive effects of open-phase DBS and the other was dissatisfied with
the overall effects of DBS.1 No further analysis was performed on these subjects. Overall there
was a decrease in Y-BOCS score from baseline throughout the 8-month open stimulation phase,
as demonstrated in Table 4. Mean scores during ON/OFF periods, as well as changes between
ON and OFF periods during the double-blind phase were calculated, as demonstrated in Table 4
as well. The mean Y-BOCS score decrease from sham to active stimulation in the entire sample
of 14 subjects was 8.8 points (SD of 9.1; 95% CI, 3.6-14.1; P.003).1 After a correction for
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period effects, stimulation “caused a substantial (mean, 8.3 [2.3] points [25%]) and statistically
significant (P=.004) reduction in the Y-BOCS total score during the double-blind phase.”1
As seen in Table 2, the NNT was calculated to be 2 patients. It is important to note that
there were 9 responders out of 16 total subjects; however, the number of responders was
calculated at the conclusion of the entire 21 month study. The double-blind crossover phase was
followed by a 12 month maintenance phase, in which all participating subjects received active
stimulation.1 Also crucial to the results is the fact that for all but 4 subjects, the blinded status of
the stimulator was lifted due to abrupt worsening of symptoms.1
Table 4. Denys et al1 Changes in OCD Symptom Severity During Double-Blind Crossover
Period
Variable

Mean
Baseline
(SD)

After 8 mos of
Stimulation
(SD)

Start of Crossover Period

Weeks 1-2
Group 1 (n=6)
34.2 (3.6)
23.3 (9.9)
After
Y-BOCS Total
Stimulation On:
Score
25.8 (9.3)
Group 2 (n=8)
33.4 (3.6)
18.7 (10.6)
After
Y-BOCS Total
Stimulation Off:
Score
29.5 (11.4)
a. All information from this table was taken directly from Denys et al1

Weeks 3-4
After
Stimulation Off:
30.7 (4.5)
After
Stimulation On:
17.6 (10.1)

Change Between
Weeks 1-2 and
Weeks 3-4
Mean (SD)
[95% CI]
4.9 (7.6) [12.9 to 3.2]

P
Value
.18

11.9 (9.3)
[4.0 to 19.7]

.009

In the Denys et al study1, two of the sixteen total subjects refused to enter the doubleblind phase of the study and only completed the open phase. Out of the remaining fourteen
subjects, ten individuals requested the blinded status of the stimulation was lifted due to
worsening of symptoms, as previously stated. An array of adverse events were reported and
these can be split into surgery related, device related and stimulation related events. Issues such
as infection at the incision site and numbness at the incision site were just a sample of the
adverse events reported from surgery, with none of these being permanent.1 Feelings of
electrical current around the neurostimulator and feelings of the neurostimulator in the chest
were device-related complaints reported by subjects, with some being permanent.1 Lastly,
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twenty-two different stimulation related effects were reported, with hypomanic symptoms being
the most common complaint.1 A few of these complaints, such as forgetfulness, were reported to
be permanent.1
Discussion
Many previous studies have been done concerning the effects of deep brain stimulation
on movement disorders, such as Parkinson’s Disease. DBS for Parkinson’s Disease has become
much more wide-spread and accessible throughout the past decade.9 Contrastingly, DBS and its
effects on psychiatric disorders, such as OCD, is a much less familiar territory in terms of
research and practice. In 2009, the FDA approved the “Medtronic Reclaim DBS therapy,” which
is “indicated for bilateral stimulation of the anterior limb of the internal capsule” for “severe,
treatment-resistant obsessive compulsive disorder (OCD).”10 The FDA also issued a warning of
the potential danger of excessive DBS causing damage to neuronal tissue, which is a truly
significant concern that all clinicians and patients must take into account.10 The FDA guidelines
are very specific, indicating DBS only for the anterior limb of the internal capsule, an area of the
brain not even studied in Goodman et al7.10 Not only are indications for DBS in OCD sparse, but
so is the availability of such a treatment. Most DBS procedures for OCD are performed only at
major academic hospitals in large metropolitan areas. In addition, Medicare does cover DBS as
a treatment for OCD; however, many private insurance companies do not.11
The limitations to each of the three studies being reviewed are numerous, and much more
research must be carried out before DBS takes the place of anterior capsulotomy for the
treatment of refractory OCD. Currently, anterior capsulotomy is the most prevalent,
neurosurgical “last-resort” option for this illness and it is with hope that DBS will eventually be
more successful than invasive capsulotomy.12 Each of the three studies reviewed contained no
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more than 20 subjects to analyze, a sample size that is significantly small for research and
statistical analysis purposes. Also, the desperation of the subjects being studied and the lastresort context of DBS created a “fertile context for placebo responses.”6 In addition, many of the
subjects developed a sense of the stimulator being ON vs OFF through a perceived somatic
sensation.6 This sense could have muffled the blind nature of the studies. In one study, the
majority of subjects even refused to allow the blind status to be continued. Much more focus
must also be put on finding the optimal stimulation parameters for an individual because this has
the ability to greatly influence outcome.
Conclusion
The studies reviewed demonstrate inconclusive evidence as to whether or not deep brain
stimulation (DBS) is an effective treatment for refractory obsessive-compulsive disorder (OCD)
in adults. The Goodman et al7 study is the only study that concluded that DBS is a “promising
therapy of last resort for carefully selected cases of severe and intractable OCD.”7 Denys et al1
and Abelson et al6 admit to its potential, but are weary of widespread use without intense further
research. In the future it would be advantageous to greatly improve the actual stimulator
engineering in order to dissolve variables such as battery life and function. Also, more strict
DBS parameters must be explored before the widespread use of DBS in refractory OCD. In
addition, studies comparing anterior capsulotomy to DBS for the treatment of refractory OCD
would be enlightening to this field of research.

Luczyszyn, OCD & Deep Brain Stimulation 12	
  
REFERENCES
1. Denys D, Mantione M, Figee M, et al. Deep brain stimulation of the nucleus accumbens for
treatment-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2010;67(10):10611068.
2. Storch EA, Lack C, Merlo LJ, et al. Associations between miscellaneous symptoms and
symptom dimensions: An examination of pediatric obsessive-compulsive disorder. Behaviour
Research and Therapy. 2001;45:2593-2603
3. DuPont RL, Rice DP, Shiraki S, et al. Economic costs of obsessive-compulsive disorder.
Medical Interface. 1995; 8(4) 102-109. http://www.ncbi.nlm.nih.gov/pubmed/10141765.
Accessed October 2, 2011
4. Fireman B, Koran LM, Leventhal JL, et al. The Prevalence of clinically recognized obsessivecompulsive disorder in a large health maintenance organization. The American Journal of
Psychiatry. 2001; 158: 1904-1910. http://ajp.psychiatryonline.org/cgi/content/full/158/11/1904.
Accessed October 2, 2011
5. Shah DB, Pesiridou A, Baltuch GH, et al. Functional neurosurgery in the treatment of severe
obsessive compulsive disorder and major depression: overview of disease circuits and
therapeutic targeting for the clinician. Innovations in Clinical Neuroscience. 2008;5(9): 24-33.
http://www.innovationscns.com/functional-neurosurgery-in-the-treatment-of-severe-obsessivecompulsive-disorder-and-major-depression-overview-of-disease-circuits-and-therapeutictargeting-for-the-clinician. Accessed October 2, 2011.
6. Abelson JL, Curtis GC, Sagher O, et al. Deep brain stimulation for refractory obsessivecompulsive disorder. Biol Psychiatry. 2005;57(5):510-516.

Luczyszyn, OCD & Deep Brain Stimulation 13	
  
7. Goodman WK, Foote KD, Greenberg BD, et al. Deep brain stimulation for intractable
obsessive compulsive disorder: pilot study using a blinded, staggered-onset design. Biol
Psychiatry. 20;67(6):535-542.
8. Federici A, Summerfeldt LJ, Harrington JL, et al. Consistency between self-report and
clinician administered versions of the Yale-Brown Obsessive-Compulsive Scale. Journal of
Anxiety Disorders. 2010; 24(7): 729-733
9. National Institute of Neurological Disorders and Stroke. NINDS Deep Brain Stimulation for
Parkinson’s Disease Information Page. Available at
http://www.ninds.nih.gov/disorders/deep_brain_stimulation/deep_brain_stimulation.htm.
Accessibility verified December 15, 2011
10. Federal Drug Administration. Summary of Safety and Probable Benefit. Available at
http://www.accessdata.fda.gov/cdrh_docs/pdf5/H050003b.pdf/. Accessibility verified December
11, 2011.
11. UCSF Department of Neurological Surgery. FAQ: Deep Brain Stimulation for Obsessive
Compulsive Disorder. Available at http://neurosurgery.ucsf.edu/index.php/deep-brainstimulation-for-OCD.html. Accessibility verified December 15, 2011.
12. Kondziolka D, Flickinger JC, Hudak R, et al. Results following gamma knife radiosurgical
anterior capsulotomies for obsessive compulsive disorder. Neurosurgery. 2011; 68(1): 28-32
13. Brown University. Demographics and Economics. Available at
http://biomed.brown.edu/Courses/BI108/BI108_2005_Groups/01/Econ&Demo.htm.
Accessibility verified February 4, 2012.
	
  
	
  

